Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates

Company Performance - Niagen Bioscience (NAGE) reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, compared to break-even earnings per share a year ago, representing an earnings surprise of +100.00% [1] - The company posted revenues of $31.12 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 8.99%, and showing an increase from year-ago revenues of $22.74 million [2] - Niagen Bioscience has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Stock Performance - Niagen Bioscience shares have increased approximately 72.7% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.03 on revenues of $30.95 million, and for the current fiscal year, it is $0.13 on revenues of $124.1 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where Niagen Bioscience operates, is currently in the bottom 42% of over 250 Zacks industries, which may impact the stock's performance [8]